Skip to main content
. 2024 Oct 17;4(1):100348. doi: 10.1016/j.jacig.2024.100348

Table I.

Patient characteristics related to aeroallergen testing among 1,412 adults with asthma

Characteristic Overall (n = 1,412) No testing (n = 728) Testing (n = 684) P value
Age <.001
 18-34 years 444 (31.4) 183 (25.1) 261 (38.2)
 35-44 years 257 (18.2) 114 (15.7) 143 (20.9)
 45-54 years 247 (17.5) 144 (19.8) 103 (15.1)
 55-64 years 226 (16.0) 135 (18.5) 91 (13.3)
 65+ years 238 (16.9) 152 (20.9) 86 (12.6)
Sex .35
 Male 308 (21.8) 166 (22.8) 142 (20.7)
 Female 1,104 (78.2) 562 (77.2) 542 (79.2)
Race <.001
 American Indian or Alaskan Native 8 (0.6) 0 (0.0) 8 (1.2)
 Asian 65 (4.6) 33 (4.5) 32 (4.7)
 Black 517 (36.6) 232 (31.9) 285 (41.7)
 Native Hawaiian or other Pacific Islander 1 (0.1) 0 (0.0) 1 (0.1)
 White 821 (58.1) 463 (63.6) 358 (52.3)
Ethnicity .02
 Not Hispanic or Latino 1,377 (97.5) 717 (98.5) 660 (96.5)
 Hispanic or Latino 35 (2.5) 11 (1.5) 24 (3.5)
Insurance <.001
 Commercial 716 (50.7) 358 (49.2) 358 (52.3)
 Medicaid 375 (26.6) 170 (23.4) 205 (30.0)
 Medicare 321 (22.7) 200 (27.5) 121 (17.7)
BMI .84
 Normal 407 (28.8) 220 (30.2) 187 (27.3)
 Overweight 413 (29.2) 207 (28.4) 206 (30.1)
 Class I obesity 265 (18.8) 136 (18.7) 129 (18.8)
 Class II obesity 158 (11.2) 80 (11.0) 78 (11.4)
 Class III obesity 169 (12.0) 85 (11.7) 84 (12.3)
Smoking category .23
 Never 965 (68.3) 483 (66.3) 482 (70.5)
 Former 322 (22.8) 178 (24.5) 144 (21.0)
 Current 125 (8.9) 67 (9.2) 58 (8.5)
COPD 111 (7.9) 57 (7.8) 54 (7.9) .96
Chronic rhinitis 1,328 (94.1) 652 (89.6) 676 (98.8) <.001
Inhaler category in the 12-month period before the index visit .14
 No ICS 724 (51.3) 352 (48.4) 372 (54.4)
 ICS only 195 (13.8) 110 (15.1) 85 (12.4)
 ICS/LABA 412 (29.2) 223 (30.6) 189 (27.6)
 ICS/LABA and LAMA 81 (5.7) 43 (5.9) 38 (5.6)
OCS bursts in the 12-month period before the index visit .70
 0 930 (65.9) 484 (66.5) 446 (65.2)
 1 282 (20.0) 138 (19.0) 144 (21.1)
 2-3 149 (10.6) 77 (10.6) 72 (10.5)
 4 or more 51 (3.6) 29 (4.0) 22 (3.2)
Asthma ED visit in the 12-month period before the index visit 36 (2.5) 16 (2.2) 20 (2.9) .39
Asthma hospitalization in the 12-month period before the index visit 21 (1.5) 10 (1.4) 11 (1.6) .72
Step-up therapy after the index visit 491 (34.8) 234 (32.1) 257 (37.6) .03

Data are presented as nos. (%). Patients who did not receive any testing (n = 728) were compared with patients who received any SPTs or serum-specific IgE tests on or within 90 days of index allergy/immunology visit (n = 684) by chi-square test.